Volibris contraindicated in idiopathic pulmonary fibrosis

Volibris (ambrisentan) must not be used in patients with idiopathic pulmonary fibrosis (IPF), the manufacturer has warned in a letter to healthcare professionals.

Idiopathic pulmonary fibrosis occurs most often in patients aged between 50 and 70 years | SCIENCE PHOTO LIBRARY
Idiopathic pulmonary fibrosis occurs most often in patients aged between 50 and 70 years | SCIENCE PHOTO LIBRARY

The new contraindication follows the early termination of the ARTEMIS-IPF study, which was investigating the potential of ambrisentan to slow disease progression in patients with IPF. Evaluation of the primary endpoint components indicated higher rates of respiratory hospitalisation, mortality and decreases in respiratory function in patients who received ambrisentan than in those on placebo.

Review patients

Patients with IPF who are currently receiving ambrisentan should be carefully assessed and alternative therapies should be considered.

View Volibris drug record

Further information: GlaxoSmithKline

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Prescribers reassured over metformin contamination

Prescribers reassured over metformin contamination

Trace amounts of the potential carcinogen N-nitrosodimethylamine...

Drug shortages - live tracker

Drug shortages - live tracker

Removed: Zovirax Suspension.
Use our constantly...

Avoid benzodiazepines in opioid-dependent patients, GPs reminded

Avoid benzodiazepines in opioid-dependent patients, GPs reminded

Prescribing benzodiazepines in opioid-dependent individuals...

Flu antivirals approved for NHS prescribing as cases increase

Flu antivirals approved for NHS prescribing as cases increase

GPs can now prescribe antiviral medicines for flu prophylaxis...